EGFR and non-small cell lung carcinoma: The acquisition of a second-site EGFR T790M mutation in exon 20 was reported in more than half of NSCLC resistance cases12–15, conferring resistance to first- and second-generation EGFR-TKI and sensitivity to the sole third-generation inhibitor16.